Related references
Note: Only part of the references are listed.Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers
G Mukwaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
CS Ernest et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel
PG Yeni et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effects of HIV-1 entry inhibitors in combination
C Tremblay
CURRENT PHARMACEUTICAL DESIGN (2004)
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers
TR MacGregor et al.
HIV CLINICAL TRIALS (2004)
Role of P-glycoprotein in pharmacokinetics - Clinical implications
JH Lin et al.
CLINICAL PHARMACOKINETICS (2003)
The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)
DP Olson et al.
AIDS (2002)
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
BA Larder et al.
AIDS (2000)
Share Paper
